Thera-SAbDab

IBRITUMOMAB

> Structural Summary

Therapeutic	Ibritumomab
Target	MS4A1/CD20
Heavy Chain	QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSA
Light Chain	QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLELK
100% seqID Fv Structure	3bky [Fvs: HL]
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

100% seqID Structure	3bky [Fvs: HL]

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder2
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Whole mAb
Isotype	G1
Highest Clinical Trial (Aug '24)	Approved
Estimated Status (Aug '24)	NFD
Recorded Developmental Technology
INN Year Proposed	1999
INN Year Recommended	2000
Companies Involved	Biogen, Schering, Spectrum Pharmaceuticals
Conditions Approved	Non-Hodgkin's lymphoma
Conditions Active	na
Conditions Discontinued	Diffuse large B cell lymphoma, Mantle-cell lymphoma, Marginal zone B-cell lymphoma, Multiple myeloma
Notes	Sequence sourced through DrugBank. ADC with tiuxetan

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy